NovAccel raises approximately ¥290m in post-seed extension
XTech Fund 3, INOUE CORPORATION and individual investors backed the medical-isotope technology company.
NovAccel announced approximately ¥290 million in a post-seed extension on November 17. XTech Fund 3, INOUE CORPORATION and individual investors subscribed to new shares. The company is continuing its fundraising.
The capital will support RiSA, its compact superconducting accelerator for medical-isotope production, and development of actinium-225 manufacturing processes. NovAccel also plans to build sample-supply and quality-control capabilities and prepare for larger-scale production.
Use of funds
RiSA accelerator and Ac225 manufacturing process
Sample supply and quality control
Business development and scale-up preparation